Heterogeneity of human adipose blood flow by Levitt, David G
BioMed  Central
Page 1 of 21
(page number not for citation purposes)
BMC Clinical Pharmacology
Open Access Research article
Heterogeneity of human adipose blood flow
David G Levitt*
Address: Department of Integrative Biology and Physiology, University of Minnesota, 6-125 Jackson Hall, 321 Church St. S. E., Minneapolis, MN 
55455, USA
Email: David G Levitt* - levit001@umn.edu
* Corresponding author    
Abstract
Background: The long time pharmacokinetics of highly lipid soluble compounds is dominated by
blood-adipose tissue exchange and depends on the magnitude and heterogeneity of adipose blood
flow. Because the adipose tissue is an infinite sink at short times (hours), the kinetics must be
followed for days in order to determine if the adipose perfusion is heterogeneous. The purpose of
this paper is to quantitate human adipose blood flow heterogeneity and determine its importance
for human pharmacokinetics.
Methods: The heterogeneity was determined using a physiologically based pharmacokinetic model
(PBPK) to describe the 6 day volatile anesthetic data previously published by Yasuda et. al. The
analysis uses the freely available software PKQuest and incorporates perfusion-ventilation
mismatch and time dependent parameters that varied from the anesthetized to the ambulatory
period. This heterogeneous adipose perfusion PBPK model was then tested by applying it to the
previously published cannabidiol data of Ohlsson et. al. and the cannabinol data of Johansson et. al.
Results: The volatile anesthetic kinetics at early times have only a weak dependence on adipose
blood flow while at long times the pharmacokinetics are dominated by the adipose flow and are
independent of muscle blood flow. At least 2 adipose compartments with different perfusion rates
(0.074 and 0.014 l/kg/min) were needed to describe the anesthetic data. This heterogeneous
adipose PBPK model also provided a good fit to the cannabinol data.
Conclusion: Human adipose blood flow is markedly heterogeneous, varying by at least 5 fold. This
heterogeneity significantly influences the long time pharmacokinetics of the volatile anesthetics and
tetrahydrocannabinol. In contrast, using this same PBPK model it can be shown that the long time
pharmacokinetics of the persistent lipophilic compounds (dioxins, PCBs) do not depend on adipose
blood flow. The ability of the same PBPK model to describe both the anesthetic and cannabinol
kinetics provides direct qualitative evidence that their kinetics are flow limited and that there is no
significant adipose tissue diffusion limitation.
Background
The physiologically based pharmacokinetic (PBPK)
approach describes the drug kinetics in terms of a realistic
physiological model that accurately represents the indi-
vidual tissue volumes, perfusion rates and tissue/blood
partition coefficients. Because adipose tissue represents
from 15 to 50% of body weight, it is one of the most
important factors in these models. The standard reference
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human adipose blood flow value of about 28 ml/kg/min
[1] is based on Xenon washout measurements [2] of the
local flow to a roughly 0.1 ml tissue region. These local
measurements are unlikely to be representative of the
whole body adipose tissue. An alternative approach is to
measure the whole body kinetics of a highly lipid soluble
solute, interpreting the kinetics of the slowly equilibrating
compartment in terms of the average adipose perfusion
[3]. This paper describes an extension of this latter
approach. A detailed human PBPK model is developed
which accurately describes the different organ volumes
and flows and then the kinetics of highly lipid soluble sol-
utes are used to calibrate the adipose tissue perfusion rate.
In addition to determining the average adipose perfusion
rate, this analysis also quantitates the heterogeneity of adi-
pose perfusion. The adipose PBPK model derived from
this analysis is then used to investigate the human phar-
macokinetics of the class of persistent lipophilic solutes
(e.g. dioxins, DDT, PCBs). Modeling is especially impor-
tant for this class of compounds because their human
pharmacokinetics cannot be accurately measured experi-
mentally because of their very slow clearance rates.
This paper describes the PBPK modeling of a remarkable
series of measurements of the pharmacokinetics of the
volatile anesthetics isoflurane, sevoflurane and desflurane
by Eger and colleagues [4,5]. They measured the ventila-
tion rate and the inspired, mixed and end tidal gas con-
centration for 6 days following a 30 minute uptake in
normal volunteers. The volatile anesthetics have two
properties that make them ideally suited for studying adi-
pose blood flow: 1) they have negligible rates of metabo-
lism and their rate of uptake and washout from the body
is determined by alveolar ventilation, which can be
directly measured experimentally; and 2) their tissue/
blood partition coefficients have been experimentally
measured and are determined primarily by their oil/water
partition and the tissue fat fraction. These two factors
reduce the number of adjustable parameters in the PBPK
model, increasing ones confidence in the estimates of the
adipose blood flow.
The time constant (T) for adipose tissue equilibration is
described by (assuming a well mixed, flow limited tissue):
For the volatile anesthetics discussed here, T is the range
of about 500 min to 3 days for the estimated range of het-
erogeneous perfusion rates (Table 1) and partition coeffi-
cients (Table 2). The PBPK analysis is divided into two
time periods: For the first time period (0 to 180 minutes)
which is much less than T, all the adipose tissue behaves
like an infinite sink and the analysis provides a measure of
the total (or average) adipose perfusion, independent of
the flow heterogeneity. During the long time period (180
min to 6 days) the adipose tissue becomes saturated and
the heterogeneity of the flow becomes important. In order
to resolve the flow heterogeneity it is essential to extend
the pharmacokinetic measurements out to 2 or more
days. Experimental human data for these times periods
are very limited (Table 1). The volatile anesthetic data of
Eger and colleagues [4,5] used here probably represents
the most accurate and extensive available data set.
The experimental data are modeled using PKQuest [6], a
general, freely distributed pharmacokinetic and PBPK
software routine that has now been applied to more than
25 different solutes with a wide range of pharmacokinetic
properties [6-15]. A single set of optimized PBPK human
parameters (eg. tissue volume, flow) has been developed
that accurately describes the pharmacokinetics of a wide
range of solutes. The sensitivity of the model parameters
varies from solute to solute and the use of a large range of
solutes provides a more stringent limit on the parameters.
For example, the human muscle blood flow was deter-
mined by modeling the pharmacokinetics of D2O. In a
previous applications of PKQuest to highly lipid soluble
T
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Table 1: Model human adipose blood flow heterogeneity. 
Solute Ref Ave
F l/kg/min
F1 l/kg/min V1 fract F2 l/kg/min V2 fract F3 l/kg/min V2 fract Time Method
Volatile 
Anesthetics
This ms. 0.044 0.0739 0.5 0.0141 0.5 6 days PBPK N = 2
0.044 0.095 0.33 0.031 0.33 0.0059 0.33 6 days PBPK N = 3
[38] 0.071 0.213 .26 0.022 0.74 5 days PBPK N = 2
0.05 0.097 .41 0.019 0.59
[4, 5] 0.06–0.071 .11–.15 ≈ 0.5 0.021–0.024 ≈ 0.5 6 days Compartmental
Propofol [14] 0.042 0.042 1.0 600 min PBPK N = 1
Toluene [55] 0.032 0.032 1.0 4 days PBPK N = 1
Toluene [53] 0.024 0.042 0.4 0.013 0.5 0.0 0.1 20 hr PBPK N = 2
Styrene [54] 0.028 0.052 0.4 0.014 0.5 0.0 0.1 20 hr PBPK N = 2
(Vi = fraction of total adipose volume in compartment i; Fi = perfusion rate in compartment i). (Note: in toluene [53] and styrene [54] PBPK model 
it is assumed that 10% of the adipose tissue has zero blood flow).BMC Clinical Pharmacology 2007, 7:1 http://www.biomedcentral.com/1472-6904/7/1
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solutes [8,14], a single homogeneous adipose tissue
model was acceptable because the experimental data did
not extend to long times. In the current analysis, which
extends out to 6 days, it will be shown that at least two
adipose compartments with significantly different per-
fusion rates are required to fit the long time data.
It is assumed in PKQuest that the adipose tissue can be
modeled using a well-stirred, flow limited model. This is
an important assumption because it means that one can
use the adipose perfusion values determined by mode-
ling, e.g., the volatile anesthetics to predict the pharma-
cokinetics of any other highly lipid soluble compound,
such as the dioxins or DDT. Although the majority of
PBPK models of these compounds use this flow limited
adipose model, there are number of research groups that
have chosen to use diffusion (or permeability) limited
models [16-19]. This greatly complicates and limits the
application of the model since the diffusion limitation
will vary in unknown ways for different solutes. The flow
limited assumption is directly tested in this paper by
determining whether the PBPK model could accurately
describe the long time experimental human pharmacoki-
netics of cannabinol [20] and cannabidiol [21] using the
adipose perfusion rates determined from modeling the
volatile anesthetics. This should not be possible if the dif-
fusion limited model is correct because these two classes
of solutes (volatile anesthetics and cannabinoids) should
have markedly different diffusion limitations.
Methods
General PBPK model
The PBPK analysis for the volatile anesthetics has been
described previously [8] and the analysis for the cannabi-
noids is similar to that used previously for propofol [14].
The arrangement of the different tissues in the PBPK
model is shown in fig. 1. The tissue parameters (blood
flow, volumes, etc.) are listed in Table 3 and are similar to
those used in previous applications of PKQuest [6-15].
The connective tissue is divided between two organs: "ten-
don" with a relatively low blood flow, and "other" with a
higher blood flow. "Bone" represents inert mass with no
blood flow. The actual bone blood flow is distributed
among the other tissues. The major change from previous
applications is that the adipose compartment has been
divided into N (arbitrary) equal mass compartments.
Table 3 shows the values for the 3 adipose compartment
model that provided the best fit to the anesthetic data.
These values are for the 70 kg, 20% fat "Standard
Human". The values are scaled for different body weight
and fat content. The fraction body fat in each study was
determined from the subjects' average age, weight and
Table 3: Physiological tissue model parameters
Tissue Weight Kg Perfusion l/Kg/min Flow l/min Fat Fraction Total Fat Kg
Blood 5.6 0.0075 0.042
Liver 1.83 0.25 0.4575 0.02 0.0366
Portal 1.525 0.75 1.14375 0.016 0.0244
Muscle 26.43 0.0225 0.594675 0.0136 0.359448
Kidney 0.3152 4 1.2608 0.0136 0.004287
Brain 1.423 0.56 0.79688 0.0176 0.025045
Heart 0.3355 0.8 0.2684 0.0136 0.004563
Lung 0.5449 0 0 0.0136 0.007411
Skin 2.643 0.1 0.2643 0.0136 0.035945
Tendon 3.05 0.01 0.0305 0.0136 0.04148
Other 5.616 0.02 0.11232 0.0136 0.076378
Bone 4 . 0 6 1 70000
Adipose 1 5.5419 0.095 0.5264805 0.8 4.43352
Adipose 2 5.5419 0.031 0.1717989 0.8 4.43352
Adipose 3 5.5419 0.0059 0.0326972 0.8 4.43352
Total 70 5.6601016 14
Table 2: Volatile anesthetic partition coefficients at 37°C.
Solute Blood/air Water/air Oil/air Adipose/Blood
Isoflurane 1.33 [56] .544 [57] 88.2 [57] 53.2
Sevoflurane 0.62 [58] .37 [59] 47 [59] 60.8
Desflurane 0.52 [58] .225 [57] 17.9 [57] 27.7BMC Clinical Pharmacology 2007, 7:1 http://www.biomedcentral.com/1472-6904/7/1
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height using the regression equation of Gallagher et. al.
[22]
Several in vitro measurements of the volatile anesthetic
tissue/water partition coefficients have been made [23-
25]. It can be shown that the partition coefficient of tissue
i can be accurately represented in terms of the fraction of
fat (fL
i) and water (fW
i) in the tissue and the oil/water par-
tition coefficient (Koil-wat) of the anesthetic [14]:
where cW and cL are the water and lipid concentration in
tissue i. It is assumed that the fat and water concentrations
are in equilibrium and the tissue/blood exchange is flow
limited so that the tissue and blood water concentrations
(cW) are equal. The values of fL for the different tissues are
listed in Table 3. They were obtained from an analysis of
the experimental tissue blood partition of a series of vola-
tile anesthetics [14]. The tissue/blood partition is then
equal to:
Tissue/Blood = (Tissue/Water)/(Blood/Water)   (3)
and the blood/water partition was determined from
experimental values for the volatile anesthetics (Table 2).
Since no experimental values are available for the tissue/
blood partition of the cannabinoids, it was estimating
from eq. (3), using eq. (2) to determine the tissue/water
and blood/water partition:
The limit on the right is valid for the very large values of
Koil-wat for the cannabinoids (24,000 or greater). In this
limit the value of the tissue/blood partition depends only
on the blood and tissue lipid fractions and becomes inde-
pendent of the value of Koil-wat. The blood lipid fraction
(fL
B) of the cannabinoids was regarded as a model param-
eter that was adjusted to optimize the fit to the data.
Volatile anesthetic data and PBPK model
The volatile anesthetic methods and data are described in
2 papers by Yasuda et. al. [4,5] that used identical meth-
odology. The subjects average age, weight, height and cal-
culated fat was 23 years, 72 kg and 182 cm (13.4% fat) for
the sevoflurane study [5] and 25, 76 and 182 (15.4% fat)
for the desflurane study [4]. Briefly, anesthesia was
induced in healthy male volunteers using midazolam
and/or thiopental and fentanyl and then 70% N2O was
administered for 30 min and the ventilation was adjusted
to produce normocapnea. Then, the test anesthetics
(either desflurane, isoflurane and halothane [4] or
sevoflurane and isoflurane [5]) were administered for 30
minutes at a nearly constant inspired concentration along
with 65% N2O. After 30 minutes, the volatile anesthetics
were discontinued, maintaining the 65% N2O, and the
washout was measured for 150 minutes, after which the
N2O was discontinued, the endotrachial tube removed
and gas samples were obtained through a mouthpiece and
non-rebreathing valve. Values of ventilation rate, inspired,
mixed and end tidal concentrations were obtained at fre-
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Schematic diagram of the arrangement of the different tissues  in the PBPK model Figure 1
Schematic diagram of the arrangement of the different tissues 
in the PBPK model. The organ "portal" refers to all the 
organs drained by the portal vein. The connective tissue is 
divided between two organs: "tendon" with a relatively low 
blood flow and "other" with a higher blood flow. The adipose 
tissue was divided into N = 1, 2 or 3 equal volume compart-
ments.
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quent intervals up to 800 minutes, and each morning
thereafter for 6–7 days. Dr. Eger generously provided
access to all of the original experimental data. The most
important additional information that was not included
in the original publications is the experimental values of
the alveolar ventilation which was determined from the
ventilation rate corrected for the dead space that was cal-
culated from the inspired, mixed and end tidal partial
pressures. A complete listing of the tabulated values, aver-
aged for all subjects, is included in the Additional file 1.
The halothane data was not included in the modeling
because of the necessity of adding additional adjustable
parameters to describe the concentration dependent
halothane metabolism.
It is necessary to introduce time dependent parameters
into the PBPK analysis because the physiological condi-
tions changed as the subject went from anesthetized to
ambulatory. The analysis was divided into 3 time periods:
The first period is from 0 to 180 minutes when the sub-
jects were anesthetized and the ventilation was adjusted to
produce normocapnia. The alveolar ventilation was
nearly constant during this period (fig. 2) and it was
assumed that it could be modeled using a constant aver-
age value. The second period was from 180 to 430 min-
utes when the subjects are recovering and are no longer
intubated. During this period, the subjects are ambula-
tory, eating, etc. and the period when the ventilation is
measured may not be representative of the average condi-
tion during each time interval. It is assumed that the alve-
olar ventilation during this period is identical to that
during the first period. The last period is from 430 min-
utes to 6 days. During this period, the ventilation was
measured once per day each morning and clearly is not
representative of the average daily ventilation rate for
these active young subjects. The average energy expendi-
ture of young subjects (and the corresponding ventila-
tion) can be as much as 1.8 times greater than the basal
rate [26]. For this reason the average ventilation rate in the
third period was treated as a constant parameter that was
adjusted to fit the data during this time period (see
Results).
It is well established that during anesthesia there are large
differences between the end tidal and arterial volatile
anesthetic concentration due to increased perfusion-ven-
tilation mismatch and shunts [27-32]. As described previ-
ously [10], perfusion-ventilation mismatch is modeled in
PKQuest by dividing the lung into, e.g., 16 equal volume
compartments with flow and ventilation characterized by
log normal standard deviations (σV and σF). In PKQuest,
the values of σV and σF are described by parameters that
have a value = 1 for normal ambulatory humans. During
the first period, σ (= σV = σF) is adjusted to fit the observed
end alveolar concentration (see Results). It is assumed
that σ is reduced by a factor of 2 during the second period
and back to the normal value during the last period. In
addition, a venous-arterial shunt was included which was
set to 8% during the first (anesthetized) period [29], and
then reduced to the normal value of 2% during the second
two periods. It is assumed that there was no significant
metabolism or skin loss of the anesthetics, consistent with
the 100% 6 day ventilatory recovery analysis of Yasuda et.
al. [4,5]. In order to scale for differences in inspired con-
centration (constant during 30 minute uptake), all plots
are in terms of P/Pinsp where P is the end tidal partial pres-
sure.
In order to characterize the adipose flow heterogeneity the
adipose tissue was divided into N (= 1, 2 or 3) equal vol-
umes with flows adjusted to optimally fit the data and the
quality of the model fit was determined for each value of
N. The adipose tissue compartments (exchange time con-
stants > 500 minutes) will be far from saturation during
the first time period (0 to 180 minutes). During this
period the adipose tissue behaves like an infinite sink so
that the kinetics depend only on the total adipose blood
flow and are relatively independent of the heterogeneity.
The total adipose blood flow was determined by optimiz-
ing the fit to this early time data using a homogeneous (N
= 1) adipose model. For the N adipose compartments,
there were N adjustable parameters representing: 1) the
total adipose blood flow (determined from fitting the N =
1 model to the short time data) and 2) the fraction of the
total flow in the first N-1 compartments (determined
from fitting the long time data). In addition, there where
two other adjustable parameters: 1) the value of perfusion
ventilation mismatch (σ) during the first period, and 2)
the average ventilation rate in the last period. All other
parameters were determined either from experimental
measurements (Table 2) or use of the previously derived
"Standard Human" PBPK model (Table 3). The identical
parameter set was used for all 3 anesthetics (and 4 data
sets since there were two sets of isoflurane data). The opti-
mal parameter set was determined by finding the set of
values that gave the best fit as measured by the average
weighted residual error (WRE = abs((model-exp))/
model). In addition, the weighted residual sum of squares
(WRSS = sum [sqr{(model-exp)/model}] was deter-
mined. The Akaike criterion (= Nln(WRSS)+2p, N = # of
data points, p = # of parameters) was used to compare the
different values of N [33]. The values of the blood/water,
blood/air and oil/water partition coefficients were deter-
mined from the experimental value of blood/air (Kbair),
water/air (Kwair) and oil/air (Koair) listed in Table 2. The
tissue/blood partition (Table 2) was determined from eqs.
(2) and (3) with the tissue lipid fraction (fL
i) listed in
Table 3.BMC Clinical Pharmacology 2007, 7:1 http://www.biomedcentral.com/1472-6904/7/1
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Alveolar ventilation rate for the sevoflurane (top) [5] and desflurane (bottom) [4] study Figure 2
Alveolar ventilation rate for the sevoflurane (top) [5] and desflurane (bottom) [4] study. The line represents the average value 
for the first 180 minutes when the subjects were anesthetized.
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Cannabinoid data and PBPK model
The data and experimental methodology is described in
the cannabinol [20] and cannabidiol [21] publications.
Deuterium labeled compounds were administered to nor-
mal young male volunteers either by smoking or by a 2
min 20 mg IV infusion and plasma values were followed
for 3 days by GC/MS. The subjects average age, weight,
height and calculated percent fat was 25 years, 72.17 kg
and 178.8 cm (15.1% fat) for the cannabinol study and
26.4, 78.6 and 183 (16.1% fat) for the cannabidiol study.
A constant set of PBPK parameters was used for the 3 days.
Only the IV data was used.
The heterogeneous adipose model obtained from mode-
ling the volatile anesthetic data was used unchanged for
the cannabinoids. The values of the oil/water partition
coefficients listed in Table 4 were determined by extrapo-
lation from the octanol/water values (see Additional file 2
for details). Only two adjustable parameters were used to
optimize the model fit to this data: 1) the liver cannabi-
noid clearance; and 2) the fat fraction of blood (fL
B) which
was used (eq. (4)) to determined the tissue/blood parti-
tion coefficient. The optimal value of fL
B was 0.0075 and
the corresponding values of the blood/water (eq. (2)) and
adipose/blood (eq. (4)) partition coefficients are listed in
Table 4.
Results
Early time volatile anesthetic homogeneous (N = 1) 
adipose PBPK model
This section describes the model fitting during the period
the subjects were anesthetized (0 to 180 minutes). During
this period, the alveolar ventilation was nearly constant
(fig. 2) and a constant value was used for this period equal
to the average experimental value. The average value was
3.65 liters/min for the sevoflurane study (fig. 2, top) and
3.9 liters/min for the desflurane study (fig. 2, bottom).
This difference is roughly proportional to the difference in
the average body weights for the two studies (72 versus 76
kg).
As discussed above, the kinetics for this early period
depend primarily on the total adipose blood flow and are
relatively independent of the adipose heterogeneity. Thus
for this period one can use a single adipose compartment
and there are only two adjustable parameters: 1) the aver-
age adipose tissue perfusion rate (FT); and 2) the value of
σ which characterizes the perfusion ventilation mismatch
during this period when the subjects are anesthetized. The
optimal values were obtained by minimizing the WRE for
the four data sets (Sevoflurane, Desflurane, IsofluraneS
and IsofluraneD) where the subscripts S and D refer to the
sevoflurane and desflurane study, respectively. It was
found by trial and error that parameters that optimized
the fit to IsofluraneS were usually optimal for the entire
data set. In this section, only the fits to the IsofluraneS data
(figs. 3 and 4) are shown. See figs. 5, 6, 7, 8 for the model
fits for the other solutes.
The optimal fit was for an FT of 0.044 liters/kg/min and a
σ = 3 (where σ = 1 is the value for normal humans [10]).
Figure 3 shows the model fits to the IsofluraneS data with
σ = 3 and FT varying from 0 to 1.5 times the optimal value.
In order to emphasize the quality of the fit, the data has
been plotted both on an absolute scale (top) and as the
semi log plots of 1 - P/Pinsp during uptake (bottom, left)
and P/Pinsp during washout (bottom, right). (P and
Pinsp refer to the end tidal and inspired partial pressure,
respectively).
Figure 4 shows the experimental IsofluraneS end tidal data
and the model end tidal and arterial concentrations using
the optimal FT (= 0.044) and σ = σV = σF varying from the
normal human value (= 1) to 4 times the normal value (=
4). For the optimal value (σ = 3) during this anesthetized
period, the end tidal partial pressure is about 17% greater
than the arterial during uptake.
Long time volatile anesthetic pharmacokinetics and the N 
compartment adipose PBPK model
Figure 5 shows that the optimal homogeneous (N = 1)
model discussed above (FT = 0.044) provides a poor fit to
the long time (6 day) anesthetic experimental data. As dis-
cussed in the Methods, heterogeneity of the adipose blood
flow was characterized by dividing it into N equal weight
compartments and determining the flow in each compart-
ment that optimized the fit to the experimental data. As
the number of adipose tissue compartments is increased,
it is essential to keep the total flow (i.e. average perfusion
rate FT = 0.044 l/min/kg) fixed in order to maintain the fit
to the early time data. Thus, there is one additional adjust-
able parameter for the N = 2 case (the fraction of the total
flow in the first compartment) and two additional param-
eters for the N = 3 case (the fraction of the total flow in
compartments 1 and 2). Figure 6 shows the semi-log plots
of the optimal fit to the data for the N = 2 case. The semi-
Table 4: Cannabinoid partition coefficients
Solute Oil/Water Blood/water Adipose/Blood
Cannabinol 257,000 1928 106.6
Cannibidiol 24,000 181 106.1BMC Clinical Pharmacology 2007, 7:1 http://www.biomedcentral.com/1472-6904/7/1
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Comparison of IsofluraneS early time experimental data (squares) and model predictions (line) for the one adipose compart- ment (N = 1) PBPK model for adipose perfusion rates (FT) varying from 0 to 0 Figure 3
Comparison of IsofluraneS early time experimental data (squares) and model predictions (line) for the one adipose compart-
ment (N = 1) PBPK model for adipose perfusion rates (FT) varying from 0 to 0.066 l/kg/min. The optimal value of σ (= 3) is 
used. The top panel shows an absolute plot of the (end tidal partial pressure)/(inspired partial pressure) (= P/Pinsp) versus time. 
The bottom panels show semi log plots of 1 - P/Pinsp during the 30 minute uptake period (left) and P/Pinsp (right) during the 
150 minute washout period.
     
Washout 
IsofluraneS: 
 
Adipose perfusion: 
                 0.044 l/min/kg 
                 0.066 l/min/kg 
                 0.022 l/min/kg 
                  0.0 l/min/kg 
N = 1 
Uptake BMC Clinical Pharmacology 2007, 7:1 http://www.biomedcentral.com/1472-6904/7/1
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log plots for the N = 3 case are shown in fig. 7 (long time)
and fig. 8 (short time). Table 1 (top 2 rows) summarizes
the perfusion rates in the different adipose compartments
for the N = 2 and N = 3 models and Table 5 lists the value
of the WRE, WRSS and the Akaike number for the differ-
ent solutes, time periods and value of N.
Comparison of IsofluraneS early time experimental data (squares) and model predictions for the one adipose compartment (N  = 1) PBPK model for σ (measure of perfusion-ventilation mismatch) varying from 1 (normal value) to 4 Figure 4
Comparison of IsofluraneS early time experimental data (squares) and model predictions for the one adipose compartment (N 
= 1) PBPK model for σ (measure of perfusion-ventilation mismatch) varying from 1 (normal value) to 4. The optimal value of FT 
(= 0.044 l/kg/min) is used. The end tidal/inspired (Pend tid/Pinsp, black) and arterial/inspired (Part/Pinsp, red) partial pressures are 
shown.
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As described in the Methods, the parameters vary as func-
tion time. During the last time (430 minutes to 6 days)
when the subject is ambulatory, σ  is set to 1 (normal
value) and the average alveolar ventilation (V3) is
regarded as an adjustable parameter. In figs. 5, 6, 7, 8, the
alveolar ventilation in the last period (V3) is 1.35 (the
optimal value for the N = 3 model) times the experimental
value for the first period (V1). Figure 9 shows the relatively
small influence of variations in this parameter (V3) for
IsofluraneS.
It is assumed that cardiac output and blood tissue distri-
bution during the last time period is equal to the resting
"Standard Human" set of values (Table 3). Actually, one
would expect that during this ambulatory period there
would be significant increases in, e.g., muscle flow. How-
ever, as shown in fig. 10, even a 10 fold increase in muscle
blood flow (from 0.0225 to 0.225 l/kg/min) with an
accompanying doubling of cardiac output (from 6.36 to
12.61 l/min) during this period has a negligible effect on
the pharmacokinetics. In contrast, changes in adipose
Semi log plots of comparison of the long time washout data (squares) versus the N = 1 PBPK model (solid line) using the opti- mal value of FT (= 0.044 l/kg/min) determined from the short time modeling analysis (fig. 3) Figure 5
Semi log plots of comparison of the long time washout data (squares) versus the N = 1 PBPK model (solid line) using the opti-
mal value of FT (= 0.044 l/kg/min) determined from the short time modeling analysis (fig. 3). Results are shown for data from 
the two studies by Yasuda et. al. in which sevoflurane and isoflurane (= IsofluraneS) [5] were compared and desflurane and iso-
flurane (= IsofluraneD) [4] were compared.
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blood flow in this period (keeping the same relative dis-
tribution to the 3 adipose regions) have dramatic effects
on the kinetics (fig. 11).
PBPK model for cannabinol and cannabidiol
The N = 1 and N = 3 compartment PBPK adipose model
that provided the best fit to the anesthetic data was used
unchanged for the cannabinoid data. There are two
adjustable parameters in the cannabinoid PBPK model: 1)
the liver clearance for each cannabinoid, and 2) the value
of the fraction of lipid in blood (fL
B) which is used to
determine the tissue/blood partition coefficient (eq. (4)
and was assumed to be identical for both cannabiniods.
In selecting the parameters, the long time points (480
minutes to 3 days) were heavily weighted because these
time points have the strongest dependence on the adipose
blood flow. The optimal value of fL
B was 0.0075. This is
close to the reported value of normal human blood total
lipid of 0.0082 gm/ml [34]. The optimal values of the
liver clearance was 1.0 l/min for cannabinol (total liver
blood flow = 1.78 l/min) and 1.3 l/min for cannabidiol
(total liver flow = 1.91 l/min). Semi log plots of the short
Semi log plots of comparison of the long time washout data (squares) versus the PBPK model with two equal volume adipose  compartments with optimal perfusion rates of 0.0739 and 0.0141 l/kg/min, respectively Figure 6
Semi log plots of comparison of the long time washout data (squares) versus the PBPK model with two equal volume adipose 
compartments with optimal perfusion rates of 0.0739 and 0.0141 l/kg/min, respectively.
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and long time model fits are shown in figs. 12 and 13. The
WRE was 0.18 for cannabinol and 0.45 for cannabidiol.
Discussion
Heterogeneity of adipose blood flow
As discussed above, for solutes with a high fat solubility
(i.e. fat/water partition of 50 or greater) the adipose tissue
behaves at short times like an infinite sink so that the only
important parameter is the total adipose blood flow and
the pharmacokinetics do not depend on either the fat vol-
ume or the distribution of adipose blood flow. As the
measurement time period extends out to the time of the
adipose/blood exchange time constant, the adipose tissue
becomes saturated and the flow heterogeneity becomes
important. This can be seen by comparing the homogene-
ous (N = 1) and heterogeneous (N = 2 and N = 3) models
at short (figs. 3 and 8) and long (figs. 5, 6 and 7) times. At
short times (0 to 180 min, period 1), the N = 1 and N = 3
model fits (and weighted residual error, Table 5) are
nearly identical while at long times (430 min to 6 days,
period 3) the homogeneous (N = 1) model provides a
poor fit to the data, with a weighted residual error more
then 3 times larger than the N = 3 model (Table 5). Based
on the Akaike criteria for time period 3 (best model is the
Semi log plots of comparison of the long time washout data (squares) versus the PBPK model with three equal volume adipose  compartments with optimal perfusion rates of 0.095, 0.031 and 0.0059 l/kg/min, respectively Figure 7
Semi log plots of comparison of the long time washout data (squares) versus the PBPK model with three equal volume adipose 
compartments with optimal perfusion rates of 0.095, 0.031 and 0.0059 l/kg/min, respectively.
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one with lowest Akaike number), the N = 2 compartment
model is superior for IsofluraneS while the N = 3 model is
better for the other 3 data sets (Table 5). The differences
between the N = 2 (fig. 6) and N = 3 (figs. 7 and 8) com-
partment model are small and are probably not signifi-
cant.
The confidence one has in this PBPK model estimate of
adipose perfusion heterogeneity is, to a large extent, sub-
jective. Certainly, the smaller the number of adjustable
parameters, the more likely the model is correct. There are
4 adjustable parameters in the N = 2 model: 1) σ – the
value of the perfusion-ventilation mismatch during the
Semi log plots of comparison of the short time uptake and washout data (squares) versus the PBPK model with three equal  volume adipose compartments (N = 3) with optimal perfusion rates of 0.095, 0.031 and 0.0059 l/kg/min, respectively Figure 8
Semi log plots of comparison of the short time uptake and washout data (squares) versus the PBPK model with three equal 
volume adipose compartments (N = 3) with optimal perfusion rates of 0.095, 0.031 and 0.0059 l/kg/min, respectively.
                      N = 3
F1=0.095       F2 =0.031    F3 =0.0059
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early anesthetized time period (0 to 180 minutes); 2) FT –
the total average adipose blood flow (determined by fit-
ting the N = 1 model to the early time data); 3) F1 – the
fraction of blood flow in the first adipose compartment;
and 4) V3 – the alveolar ventilation during the 1 to 6 day
ambulatory period relative to that during the anesthetized
period. The N = 3 model has one additional parameter
(the fraction of flow in the second compartment). All the
other PBPK parameters use experimental measurements
(i.e. blood/air partition) or the previously derived "Stand-
ard Human" PBPK parameter set. The value of σ deter-
mines the relationship between the end tidal and arterial
partial pressure. The model value of σ = 3 corresponds to
an end tidal partial pressure about 17% greater than the
arterial pressure after 30 minutes uptake (fig. 4). This is
nearly identical to the experimental result of Eger and
Bahlman [32] in a similar set of subjects (normal young
volunteers). The model has only a weak dependence on V3
(fig. 9) and the model value of 1.3 times the resting value
is reasonable. It should be emphasized that the identical
set of these 4 adjustable parameters were used to fit 4 dif-
ferent sets of experimental data (influraneS, influraneD,
sevoflurane and desflurane). The good fit to 3 solutes with
significantly different partition values (Table 2) lends fur-
ther support to the validity of the model.
At short times (0 to 180 min), the non-adipose tissues
dominate the kinetics, as seen by comparing the 0.044 l/
min/kg flow versus the zero adipose blood flow (fig. 3). In
contrast, at long times, about 95% of the volatile anes-
thetic is contained in fat and the adipose tissue dominates
the pharmacokinetics. For example, in the third time
period (430 minutes to 6 days) a 10 fold increase in mus-
cle blood flow (and a corresponding 2 fold increase in car-
diac output) has no significant effect on the
pharmacokinetics (fig. 10).
Table 1 compares the current results with previous esti-
mates of adipose blood flow using lipid soluble solutes.
Using the same data as used in this study, Yasuda et. al
[4,5] estimated the adipose perfusion heterogeneity by
applying a compartmental or "mammillary" model
approach. They assumed that the kinetics could be
described by a 5 compartment model whose rate con-
stants are determined by exponential curve fitting. Making
assumptions about each compartment's tissue/blood par-
tition, these rate constants can be interpreted in terms of
volumes and flows. This approach is more general then
the PBPK model because it does not make any a priori
assumptions about tissue volumes or perfusion. However,
this is also a major weakness because, for example, the
total adipose volume and the total tissue volume do not
necessarily equal the known body fat or total body vol-
ume and the "central compartment" volume may differ
significantly from the known blood volume. The repro-
ducibility of these parameters depends on the 5 compart-
ments having clearly separable time constants. Yasuda et.
al. assumed that two of the 5 compartments were adipose.
The volumes of the two adipose compartments were
roughly similar and the perfusion rates of the slow and
fast adipose compartment were in the range of 0.022 and
0.12 l/kg/min (Table 1).
The PBPK approach used is here is closely related to the
modeling of the volatile anesthetic experimental data of
Carpenter et. al. [35-37] by Fiserova-Bergerova [38]. How-
ever, there are several important differences: 1) The exper-
imental subjects in the Carpenter et. al. studies were
undergoing nephrectomy with the possibility of con-
founding changes in PBPK parameters. In contrast, there
was no surgical intervention for the subjects used in cur-
rent analysis [4,5]. 2) The experimental values of the alve-
olar ventilation values were not available to Fiserova-
Table 5: Weighted residual error (WRE), weighted residual sum of squares (WRSS) and Akaike number for each solute, adipose 
model and time period
Solute Time period Data (# pts) N = 1 N = 2 N = 3
WRE WRSS Akaike WRE WRSS Akaike WRE WRSS Akaike
Isoflurane_S 1 45 0.062 0.329 -50.0264 0.0572 0.285 -54.487 0.0575 0.284 -52.6451
2 5 0.41 1.004 0.01996 0.0224 0.329 -3.55849 0.169 0.182 -4.51874
3 10 0.44 3.94 13.71181 0.12 0.24 -12.2712 0.125 0.226 -10.8722
Isoflurane_D 1 45 0.047 0.186 -75.6904 0.0385 0.116 -94.9374 0.0375 0.11 -95.3274
2 6 0.37 1.044 0.258357 0.189 0.285 -5.5316 0.131 0.14 -7.79668
3 9 0.32 1.096 0.825005 0.127 0.248 -10.5489 0.119 0.16 -12.4932
Sevoflurane 1 45 0.0729 0.386 -42.8363 0.0664 0.332 -47.6179 0.0648 0.32 -47.2745
2 5 0.39 0.955 -0.23022 0.242 0.364 -3.05301 0.192 0.225 -3.45827
3 10 0.36 1.657 5.050087 0.215 0.573 -3.5687 0.103 0.171 -13.6609
Desflurane 1 45 0.0869 0.866 -6.47417 0.0586 0.32 -49.2745 0.0477 0.195 -69.564
2 6 0.323 0.768 -1.58379 0.167 0.204 -7.53781 0.119 0.114 -9.02934
3 9 5.08 1416 65.30032 0.196 0.641 -2.00253 0.139 0.338 -5.76238BMC Clinical Pharmacology 2007, 7:1 http://www.biomedcentral.com/1472-6904/7/1
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Bergerova and his assumed value of 5 l/min is about 35%
larger than the experimental value in the current studies.
3) There was no correction for perfusion/ventilation mis-
match or changes in PBPK parameters between the anes-
thetized and ambulatory periods.
The average value of the PBPK adipose flow estimate in
the current study (0.044 l/kg/min, Table 1) is in good
agreement with more direct human measurements which,
of necessity, represent specific local values. The 133Xe
washout method yields values for the abdominal adipose
flow ranging from 0.025 to 0.035 l/min/kg [39-43]. Using
the [15O]-labeled water method, Virtanen obtained higher
values of 0.045 (perienal fat) to 0.059 l/min/kg (visceral
fat) [44].
All the model analyses of the lipid soluble compounds
have concluded that at least two compartments with large
volumes of distributions and significantly different time
constants are necessary to describe the long time kinetics
(Table 1). These two compartments almost certainly con-
tain large fractions of fat. For example, if these compart-
ments represented muscle, they would have to have
volumes 30 times the assigned adipose volumes and per-
fusion rates 1/30 of adipose because the tissue/blood par-
tition of adipose tissue is about 30 times that of muscle
[24]. However, the specific physiological interpretation of
the two compartments is more ambiguous. For the N = 2
model, the two adipose perfusion rates differ by a factor
of 5.2 (Table 1). Measurements of adipose blood flow in
rats using microspheres find about a 5 fold perfusion
range for different fat depots [45]. However direct meth-
ods in humans do not find large perfusion differences in
different adipose tissues (subcutaneous, visceral and peri-
renal [44] or abdominal and femoral [40]). It cannot be
determined from this PBPK analysis whether the hetero-
geneity represents a macro or microscopic heterogeneity.
Eger et. al. [46] suggested that the high flow adipose com-
partment might be an artifact of intertissue diffusion from
high blood flow tissues (e.g. kidney, intestine, dermis) to
surrounding adipose tissue. This explanation does not
seem to be consistent with the cannabinoid results, as dis-
cussed below in the "diffusion limited" section.
Pharmacokinetics of persistent lipophilic compounds 
(Dioxins, DDT, PCBs)
The pharmacokinetics of this class of compounds is char-
acterized by extremely slow excretion rates, with time con-
stants of years [47-50]. The use of PBPK models for this
solute class is one of the most important applications of
Semi log plots of the IsofluraneS long time washout data  (squares) versus the PBPK model with three equal volume  adipose compartments (N = 3) with optimal adipose per- fusion rates and muscle perfusion rates in period 3 (430 min- utes to 6 days) of 0.0225 l/kg/min (black line, the "Standard"  resting human value) or 0.225 l/kg/min (red line) Figure 10
Semi log plots of the IsofluraneS long time washout data 
(squares) versus the PBPK model with three equal volume 
adipose compartments (N = 3) with optimal adipose per-
fusion rates and muscle perfusion rates in period 3 (430 min-
utes to 6 days) of 0.0225 l/kg/min (black line, the "Standard" 
resting human value) or 0.225 l/kg/min (red line). The differ-
ence in the model results for the 10 fold change in muscle 
blood flow is so small that the two curves are superimposed.
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Vary muscle blood flow: 
 
                  F = 0.0225 l/kg/min 
                  F = 0.225 l/kg/min 
                   
Semi log plots of the IsofluraneS long time washout data  (squares) versus the PBPK model with three equal volume  adipose compartments (N = 3) with optimal perfusion rates  and alveolar ventilation during period 3 (430 minutes to 6  days) varying from V1 (= 3.65 l/min = average value during  anesthetized period) to 1.7 × V1 Figure 9
Semi log plots of the IsofluraneS long time washout data 
(squares) versus the PBPK model with three equal volume 
adipose compartments (N = 3) with optimal perfusion rates 
and alveolar ventilation during period 3 (430 minutes to 6 
days) varying from V1 (= 3.65 l/min = average value during 
anesthetized period) to 1.7 × V1.
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PBPK modeling because of the difficulty of measuring the
human pharmacokinetics for solutes with these long time
constants. Fortunately, there are some important simplifi-
cations in the PBPK model for this solute class that greatly
increase ones confidence in these models.
Firstly, these persistent compounds all have Koct-wat of
about 106or greater and the Koil-wat should be similar (see
Additional file 2). This means that the tissue/blood parti-
tion coefficient can be described by eq. (5) (the limit of
eq. (4)) and depends only on the tissue and blood lipid
fraction (fL) and is independent of the actual value of
Koil-wat.
This is a major advantage since the value of the tissue/
blood partition coefficient is the major source of uncer-
tainty in most PBPK modeling.
Secondly, if the liver clearance time constant is long com-
pared to the adipose exchange time constant, the liver
clearance becomes rate limiting and the kinetics at long
times are no longer dependent on the adipose (or any
other tissue) blood flow. In this limit, the blood concen-
tration (C(t)) can be described by a simple well stirred
one compartment model:
where Veq  is the equilibrium volume of distribution
(determined from the tissue/blood partition and volume
of each tissue) and Cl is the liver clearance. A quantitative
measure of the influence of the liver clearance on the
PBPK model kinetics is shown in fig. 14. This figures com-
pares the kinetics for the simple one compartment model
(eq. (6)) with the N = 1 and N = 3 PBPK models for can-
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Semi log plots of short (top) and long time (bottom) experi- mental washout data for cannabinol versus the PBPK model  using the identical N = 3 (black) or N = 1 (red) adipose com- partment flow rates determined from the volatile anesthetic  data Figure 12
Semi log plots of short (top) and long time (bottom) experi-
mental washout data for cannabinol versus the PBPK model 
using the identical N = 3 (black) or N = 1 (red) adipose com-
partment flow rates determined from the volatile anesthetic 
data.
    
      
 
 
           Cannabinol 
N = 3                 N = 1  
Semi log plots of the long time washout data (squares) versus  the PBPK model with three equal volume adipose compart- ments (N = 3) with average adipose perfusion rates of 0.022  (red), 0.044 (black, the optimal value) or 0.066 l/kg/min Figure 11
Semi log plots of the long time washout data (squares) versus 
the PBPK model with three equal volume adipose compart-
ments (N = 3) with average adipose perfusion rates of 0.022 
(red), 0.044 (black, the optimal value) or 0.066 l/kg/min. The 
relative perfusion rates among the 3 compartments are fixed 
at the optimal values.
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nabinol as a function of the liver clearance. (Since cannab-
inol has a Koil-wat of 257,000, its tissue/blood partition
should be identical to that of the persistent solutes, eq.
(5)). For a clearance of 1 l/min (the optimal model fit to
the experimental cannabinol data (fig. 12)), the blood
concentration has a strong dependence on the adipose
flow model. For example, at 20 days, the residual blood
cannabinol concentration for the N = 3 adipose model is
about 10 times higher than for the N = 1 model and 100
times higher than the one compartment model, and this
difference grows exponentially with time (fig. 14, upper
left). However, if the liver clearance is reduced by a factor
of 100 to 0.01 l/min, the liver clearance becomes rate lim-
iting and, after about 10 days, the kinetics for the N = 3
and N = 1 PBPK model and the one compartment model
(eq. (6) become nearly identical (fig. 14, lower right). The
one compartment time constant (T) for a clearance of
0.01 l/min is 86 days (Veq = 1237 l), much longer than the
time constant of the slowest adipose tissue compartment
(6.26 days) of the N = 3 model. Since the half time of most
persistent lipophilic compounds is a year or longer [47-
50], the simple one compartment model (eq. (6)) pro-
vides a good approximation to their long time pharma-
cokinetics. The equivalence of the PBPK and one
compartment models for a clearance of 0.01 l/min is only
valid at long times. As shown in the inset in fig. 14, the
one compartment model differs significantly from the N
= 3 PBPK model for the first 10 days. If one is interested in
modeling the early time kinetics after, e.g., a sudden expo-
sure to dioxin, it is necessary to use the complete PBPK
model with heterogeneous adipose blood flow.
Flow limited versus diffusion limited adipose models
It is assumed in the PKQuest PBPK model that the
exchange between adipose tissue and blood is flow (per-
fusion) rate limited. That is, the blood at the venous end
of the capillary equilibrates with the well mixed tissue
concentration so that the only parameter characterizing
the exchange is the adipose perfusion rate. A number of
groups have used a more complicated model in which the
rate of adipose-blood exchange is characterized by both
the perfusion rate and a diffusion limited permeability
coefficient [16-19]. Flow limited models have the major
advantage that one can use the perfusion rates determined
from one solute to predict the pharmacokinetics of any
other solute (if the adipose/blood partition coefficient is
known). This cannot be done with the diffusion limited
model since the permeability coefficient will vary from
solute to solute. The ratio of the rates of blood/tissue
exchange by diffusion and perfusion is qualitatively
described by:
where cW and cB are the water and blood concentration, F
is blood flow and DW is the aqueous diffusion coefficient.
(See the Additional file 2 for a detailed derivation of eq.
(7)). The flow (perfusion) limited model assumes that
perfusion is the slow, rate limiting process and the ratio in
eq. (7) << 1. As the value of Kbld-wat increases, the value of
the ratio increases, increasing the relative importance of
the diffusive component in limiting the rate of blood-tis-
sue exchange.
One approach to determining if the diffusive component
is limiting is to compare the pharmacokinetics of two sol-
utes that have significantly different values of Kbld-wat and,
therefore, diffusion limitation (eq. (7)). If a flow limited
model (with a fixed set of tissue flows) is able to accu-
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Semi log plots of short (top) and long time (bottom) experi- mental washout data for cannabidiol versus the PBPK model  using the identical N = 3 (black) or N = 1 (red) adipose com- partment flow rates determined from the volatile anesthetic  data Figure 13
Semi log plots of short (top) and long time (bottom) experi-
mental washout data for cannabidiol versus the PBPK model 
using the identical N = 3 (black) or N = 1 (red) adipose com-
partment flow rates determined from the volatile anesthetic 
data.
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Semi log plots of long time cannabinol washout for the simple one well mixed compartment model (green) and the PBPK N =  1 (red) and N = 3 (black) adipose models Figure 14
Semi log plots of long time cannabinol washout for the simple one well mixed compartment model (green) and the PBPK N = 
1 (red) and N = 3 (black) adipose models. Plots are shown for liver cannabinol clearance (Cl) varying from 1.0 l/min (the opti-
mal value for cannabinol) down to 0.01 l/min. The inset shows the early time result for the 0.01 l/min clearance.
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rately describe the kinetics of both solutes then this pro-
vides direct evidence that diffusion is not limiting either
solute. As described in the Results, the 3 day cannabinol
kinetics (fig. 12) can be accurately described by a flow lim-
ited model that used the identical set of adipose perfusion
rates determined from modeling of the volatile anesthetic.
Since the cannabinol Kbld-wat is about 1000 times larger
than that of the anesthetics (Tables 2 and 3), this provides
direct qualitative support that these two solutes can be
described by a flow limited PBPK model. Another argu-
ment that supports at least the qualitative validity of the
flow limited model is the agreement between the average
adipose blood flow determined using the PBPK flow lim-
ited model and direct methods using either Xe washout
[39-43] or [15O]-labeled water [44]. A diffusion limita-
tion, if it existed, should have different effects on these
three methods and they should not agree.
There are two other factors that could produce departures
from the simple flow limited model: 1) a direct arterial-
venous shunt; and 2) intertissue diffusion from high
blood flow tissues (eg. kidney, intestine, dermis) to sur-
rounding adipose tissue [46,51]. Both of these effects also
depend on the perfusion/diffusion ratio (eq. (7)) and the
agreement between the anesthetic and cannabinol model
results suggests that neither of them are important for
these solutes. These model results provide qualitative sup-
port for the flow limited model for solutes with Kbld-wat
varying from 2 volatile anesthetics) to 2000 (cannabinol).
Some PCBs have values of Koil-wat (and therefore, Kbld-wat)
that are as much as 100 times greater than that of cannab-
inol [52], with a corresponding Perfusion/Diffusion ratio
100 times greater (eq. (7)). These PCBs might have a sig-
nificant diffusion limitation.
Conclusion
The heterogeneous perfusion of human adipose tissue can
only be resolved by following the blood concentrations
for long times (2 days or more). The volatile anesthetic
pharmacokinetic studies of Eger and colleagues [4,5] rep-
resents the most accurate and complete long term data set
in the literature. The PBPK modeling of this data clearly
indicates there are at least 2 different adipose compart-
ments with perfusion rates varying by a factor of 5 or
more. Although this heterogeneity significantly influences
the long time pharmacokinetics of drugs such as cannabi-
nol or tetrahydrocannibinol that have a relatively high
liver clearance, it has an insignificant long time effect on
persistent compounds such as the dioxins or PCBs that
have very slow rates of clearance. Comparison of the
model analysis of the volatile anesthetics versus cannabi-
nol provides direct qualitative support for the validity of a
flow limited adipose tissue PBPK model.
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